A recent study based on observations at 69 leading cardiac centers around the world was published regarding Bayer Pharmaceuticals heart surgery drug Trasylol. Kidney failure, heart failure, and stroke are side effects associated with Trasylol heart surgery patients according to the study published by Mangano et al. in January 2006 in the New England Journal of Medicine (NEJM).

Each year approximately one million patients undergo surgery following a heart attack. The majority of patients who are at increased risk of bleeding during surgery have the option of one of three antifibrinolytic drugs to limit blood loss: Trasylol (Aprotinin), Amicar (aminocaproic acid), or Cyklokapron (tranexamic acid). These drugs work by inactivating an enzyme called plasmin so it stops from breaking down blood clots which helps prevent bleeding.

The observational study published in the (NEJM) raised significant concerns regarding the safety of Trasylol. The study revealed that Trasylol doubled the risk of kidney failure along with other serious side effects including stroke and heart attack. Trasylol has been on the market for use in cardiac surgery since its approval in 1993. It is estimated that as many as 10,000 patients may be on kidney dialysis due to Trasylol. Kidney failure was not associated with the less costly generic drugs aminocaproic acid and tranexamic acid according to the study.

The FDA has approved revised labeling for Trasylol following a review of safety information. On September 21, 2006, the FDA held a public meeting of the Cardiovascular and Renal Drugs Advisory Committee to discuss the safety of Trasylol. The Trasylol labeling changes are based upon the recommendations of that advisory committee. The new label states that Trasylol should only be administered to patients who are at an increased risk for blood loss during heart surgery. The label changes include a warning that Trasylol increases the risk for kidney damage. The costs associated with patients suffering from Trasylol kidney failure are significant. Average annual dialysis costs per patients are over $66,000.

Dialysis is a type of renal replacement therapy which acts as an artificial kidney for patients who have lost kidney function due to renal failure. There are two primary types of kidney dialysis treatment: hemodialysis and peritoneal dialysis. The overwhelming majority of dialysis patients receive hemodialysis where the blood is circulated outside the body through a hemodialyzer, cleaned and then returned to the patient. Hemodialysis treatments are typically performed three times per week, with each session lasting 3 to 5 hours. Dialysis involves substantial cost, whether it is hemodialysis or peritoneal dialysis.

On September 29, 2006, the FDA announced that Bayer had informed the agency of an additional Trasylol study. The result of the study suggests that in addition to serious kidney damage, Trasylol may also increase the risk of death, strokes, and congestive heart failure. It is estimated that the replacement of Trasylol with the generic drug aminocaproic acid would prevent kidney failure and related dialysis treatment in 11,050 patients per year saving more than $1 billion per year. Replacement of Trasylol with the generic drug tranexamic acid would prevent 9790 renal complications requiring dialysis each year with similar annual savings.

Trasylol kidney failure is a serious side effect that requires further study and may result in additional labeling changes. Mangano et al., in their January 26, 2006 study, suggest that given the serious risk of kidney damage and other side effects continued Trasylol use is not recommended due to the availability of less expensive generic drugs that are not associated with serious cerebrovascular events and renal dysfunction.

Steve Fields

Trasylol Kidney Failure\r For more information please visit minnesotatrasylolattorney.com

More Drugs Cited as Possibly Dangerous by the FDA
It seems that every time you turn around theres another story on the 6 oclock news citing bad drug interactions or recalls from the FDA. In the past few years, for instance, youll probably recognize Vioxx, Celebrex, Baycol and Acutane as just a few of those that captured national news attention. In the last sixty days, the Federal Drug Administration has issued recalls or warnings on several other over-the-counter or prescription drugs.Rituxan m...

Managing Your Diabetes Symptoms
Watching for symptoms and controlling your blood glucose levels should be your most important goals. this will enable you to take the appropriate steps to eradicate symptoms since there is no cure for diabetes. This will enable you to live a longer life and put an end to the long-term health risks such as heart disease and kidney failure. Talking with your doctor is recommended because knowledge is power. The more able you are to recognize th...

2 Things That Cannot Be Skipped For Diabetics
Diabetes can raise the risk of leading to heart disease. One should not treat this lightly if he or she has confirmed to be diabetic. Besides medications, urine test and exercise are the two things that cannot be skipped. Why? Please read on.When one has diabetes, he or she will be monitored by testing blood sugar instead of the normal urine test. However, patients having diabetes and high blood pressure make them more susceptible to kidney damag...

The Most Important Drugs For A Diabetic
A good diet, a healthy life style and a lot of exercise are one of the best ways to keep diabetes under control and even to prevent it. But one must not forget the medications every diabetic needs to take. Although there are several drugs every diabetic uses, one should see a physician before taking them because people can react different to the same drugs.You may find it strange but one of the oldest drugs still in use is prescribed to diabetics...

NSF-NFD - Gadolinium
NSF/NFD (nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy) is a painful and debilitating condition which involves hardening of the skin and can cause damage to internal organs. It is caused by the use of gadolinium, used in MRIs and MRAs, in patients with kidney disease.NSF/NFD was first discovered in 1997. So far it appears that only people with kidney disease develop the condition. It is rare, but very difficult to treat, and c...